Probiotic Strains Lactobacillus fermentum and Bifidobacterium breve Linked to Reduced Morbidity in Premature Infants

A recent randomized clinical trial published in *Pediatric Research* has presented evidence indicating that specific probiotic strains may reduce morbidity among premature infants. The study examined the effects of Lactobacillus fermentum CECT5716 and Bifidobacterium breve CECT7263, highlighting their potential role in improving health outcomes for this vulnerable population. Researchers conducted the trial to evaluate whether these probiotics could address common complications associated with preterm birth.

The findings suggest that administering these probiotic strains may help mitigate certain morbidities frequently observed in premature infants, though further details on the scope and scale of improvements were not disclosed in the report. This research contributes to ongoing efforts to enhance neonatal care by exploring interventions aimed at reducing health risks for preterm babies. The study marks a step forward in understanding how probiotics might be integrated into medical practices to support infant health during critical early stages of development.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 27, 2025

Related posts:

Digital Transformation in Pharma Streamlines Generic Drug Development: Data Management and Analytics See Major Improvements. FDA Introduces AI Tool Elsa to Streamline Medical Product Evaluation and Safety Analysis Walgreens Pharmacists Address Vaccine Hesitancy and Expand Co-Administration During Respiratory Season Study Explores Use of Omics and CRISPR-Cas9 to Boost Abiotic Stress Tolerance in Carrots

Author

GOAI